About Athira Pharma
Athira Pharma is a company based in Seattle (United States) founded in 2011. Athira Pharma has raised $121.04 million across 13 funding rounds from investors including Franklin Templeton, Citadel and HHS. The company has 26 employees. Athira Pharma operates in a competitive market with competitors including Tenaya Therapeutics, Orca Bio, Avita Medical, Tune Therapeutics and Organogenesis, among others.
- Headquarter Seattle, United States
- Employees 26
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website athira.com
- Social LinkedIn X Facebook
- Legal Name Athira Pharma, Inc.
- Net Profit-$96.94 M (USD)17.62as on Dec 31, 2024
- EBITDA-$95.81 M (USD)24.04as on Dec 31, 2024
- Total Equity Funding$121.04M (USD)
in 13 rounds
- Latest Funding Round$15M (USD), Grant
Dec 2020
- InvestorsFranklin Templeton
& 21 more
- Employee Count26
Funding Insights of Athira Pharma
Athira Pharma has successfully raised a total of $121.04M across 13 strategic funding rounds. The most recent funding activity was a Grant round of $15 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $121.04M
- Total Rounds 13
- Last Round Grant — $15M
- First Round $250,000
(Jul 2014)
- Investors Count 22
Latest 10 of 13 funding rounds of Athira Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $15M | Grant | – | – | |
| Sep 2020 | $15.23M | Grant | – | – | |
| Jun 2020 | $89.01M | Series B | – | Perceptive Advisors | |
| Jan 2020 | $3.82M | Series B | – | – | – |
| Jan 2019 | $1.27M | Series B | – | – | – |
| Oct 2018 | – | Grant | – | – | |
| Oct 2017 | $15.2M | Series A | – | Bruce Montgomery, Michael Montgomery | – |
| Apr 2017 | $1.4M | Series A | – | Alzheimer's Drug Discovery, Dolby Family Ventures | – |
| Feb 2016 | $10M | Series A | – | – | |
| Mar 2015 | $500,000 | Grant | – | – |
22 investors in total: 20 institutional and 2 angel.
Investors in Athira Pharma
Athira Pharma has secured backing from 22 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Franklin Templeton, Citadel and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Private investment firm focused on multiple sectors | – | vikingglobal.com | Greenwich, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Healthcare startups are funded by this corporate-backed venture capital entity. | – | lifesciventure.com | New York, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Private equity fund focused on the biotechnology sector | – | logoscapital.com | San Francisco, United States | |
Biotech funding, drug development support, and investment in life sciences. | – | sofinnova.com | - | |
Investments in multiple sectors are made by Sahsen Ventures. | – | sahsen.com | Seattle, United States | |
Venture capital fund focused on early-stage biotech, life sciences, IT, and multiple sectors | – | dolbyventures.com | San Francisco, United States |
Investor details for Athira Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Athira Pharma
31 people are tracked at Athira Pharma (13 in leadership, 13 in board & advisors, 5 in team); the tracked headcount is 26.
| Name | Role | Group |
|---|---|---|
Mark Litton | CEO | Leadership |
Javier san Martin | Chief Medical Officer | Leadership |
Liana Stein | Senior Director, Preclinical Development | Leadership |
Mark J. Litton | President & CEO | Leadership |
Kevin Church | VP of Discovery | Leadership |
Hans Moebius | Chief Medical Officer | Leadership |
Simon Daggett | Vice President Clinical Operations | Leadership |
Kai-Bin Ooi | Associate Director, Program & Portfolio Management | Leadership |
Ardelle Dennis | Senior Executive Assistant To President & Ceo, Cso, And CMO | Leadership |
Austin Pidgeon | Director, Human Resources | Leadership |
Robert Taylor | Director, Discovery Biology | Leadership |
Sherif Reda | Director, Discovery Research | Leadership |
Laury Miller | Head Of Information Technology Department | Leadership |
John M. Fluke | Director | Board & advisors |
Kelly A. Romano | Director | Board & advisors |
Joseph Edelman | Director | Board & advisors |
Barbara Kosacz | Director | Board & advisors |
James A. Johnson | Director | Board & advisors |
Michael A. Panzara | Director | Board & advisors |
Grant Pickering | Director | Board & advisors |
11 more people are available in the full profile.
Complete people profiles for Athira Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Athira Pharma
Athira Pharma is a publicly listed company on the NASDAQ with ticker symbol ATHA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Sep 2020
- Listed onNASDAQ: ATHA
- Listed entityAthira Pharma, Inc.
- Exchange sectorHealth technology
- ISINUS04746L2034
- Share price$6.75 (-6.12% on the day) · 2026-01-12
- Market capitalisation$28.4M
- EPS (diluted, trailing year)$-9.66
- Volume (last session)70,313
- Analyst consensusNeutral
Financials of Athira Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | – | -$96.9M | -$95.8M |
| 2023 | – | -$117.7M | -$126.1M |
| 2022 | – | -$95.6M | -$93.0M |
| 2021 | – | -$54.9M | -$63.5M |
| 2020 | – | -$19.9M | -$18.0M |
Detailed financial statements for Athira Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Athira Pharma
4 dated milestones of Athira Pharma across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Athira Pharma is founded.
- Funding First funding round of $250K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $15.0M.
Competitors of Athira Pharma
Athira Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Orca Bio, Avita Medical, Tune Therapeutics and Organogenesis, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. | |
| orcabio.com | 2016 | Menlo Park, United States | $192M | 66 | Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | |
| avitamedical.com | 1992 | Cambridge, United Kingdom | – | 108 | Products for regenerative and respiratory medicine are developed and distributed. | |
| tunetx.com | 2009 | Seattle, United States | $222.41M | – | Cell and gene therapies are developed via an epigenomic platform. | |
| organogenesis.com | 1985 | Canton, United States | $30M | 856 | Regenerative therapies for wound care are developed and commercialized. | |
| obsidiantx.com | 2015 | Cambridge, United States | $325M | 80 | Engineered cell and gene therapies are developed for multiple diseases. | |
| oisinbio.com | 2014 | Seattle, United States | $27.51M | – | Genetically targeted therapies for age-related diseases are developed. | |
| orthofix.com | 1980 | Lewisville, United States | – | 1,634 | Reconstructive and regenerative solutions for bone conditions are developed. |
Detailed competitors of Athira Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Athira Pharma
The website of Athira Pharma (athira.com) receives about 4.9K visits a month and ranks #4,394,066 among all websites worldwide, #5,348 in Biotechnology and Pharmaceuticals.
- Monthly visits4.9K
▲ 11% vs previous month
- Unique visitors1.9K
per month
- Global rank#4,394,066
among all websites
- Category rank#5,348
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.4
- Average visit8 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with Athira Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| agcbio.com | 100% | – | #910,858 | View details | |
| lyell.com | 99% | 14.3K | #3,232,661 | View details | |
| lundbeck.com | 84% | 137.6K | #280,857 | View details | |
bioworld.com | bioworld.com | 78% | – | #311,180 | – |
alzforum.org | alzforum.org | 47% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 9 similar websites and full traffic analytics for Athira Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 9 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Athira Pharma
Complete news archive for Athira Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Athira Pharma
10 companies that operate in the same segment as Athira Pharma (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Athira Pharma
Athira Pharma was founded in 2011 and raised its 1st funding round 3 years after it was founded.
Athira Pharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Mark Litton is the current CEO of Athira Pharma.
Athira Pharma is a funded company, having raised a total of $121.04M across 13 funding rounds to date. The company's 1st funding round was a Grant of $500K, raised on Jul 2014.
Athira Pharma has 26 employees.
Athira Pharma was established in 2011 and is headquartered in Seattle, United States. Operations center on the biotechnology sector, with emphasis placed on developing treatments for neurodegenerative conditions. The primary candidate, Fosgonimeton, targets Alzheimers disease, Parkinsons disease, and multiple dementias. Further assets in the pipeline include ATH-1020, directed at neuropsychiatric disorders, and ATH-1019, aimed at peripheral applications.
Athira Pharma's top competitors include Tenaya Therapeutics, Orca Bio and Avita Medical.
Yes, Athira Pharma is publicly traded on NASDAQ under the ticker symbol ATHA.
Athira Pharma has 22 investors. Key investors include Franklin Templeton, Citadel, HHS, Alzheimer’s Association, and RTW Investments.
Athira Pharma operates through Athira Pharma, Inc..